ArticleScientific reports2025
Attitude of patients with liver cancer toward clinical drug trials: empirical qualitative research.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patient and Caregiver Reported Barriers to Cancer Clinical Trial Participation: A Scoping Review.Cancer reports (Hoboken, N.J.) · 2026Article
- Attitudes and Willingness to Participate in Drug Clinical Trials Among Patients With Cancer: Multistage Qualitative Study.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the attitude of patients with liver cancer toward clinical drug trials and promote the development of clinical drug trials in patients with liver cancer. Qualitative study. In this study conducted in a tertiary hospital, we conducted in-depth interviews in 19 patients with liver cancer, including those who were: (1) diagnosed with primary liver cancer according to the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)"; (2) without cognitive or language impairment and were able to express their thoughts; and (3) willing to participate in the study and provided written informed consent. We excluded those with serious physical diseases or other malignant tumors and mental disorders. The attitudes of patients with liver cancer toward clinical drug trials were evaluated along with the awareness of clinical drug trials and factors affecting their participation in order to promote the development of clinical drug trials for this population. We summarized the attitude of patients to clinical drug trials into two themes. The first involved differences in patients' awareness of clinical drug trials, which comprised lack of awareness, doubts and worries, blind trust in authoritative sources, and rational participation. The second highlighted factors influencing participation in clinical drug trials, which included: (1) positive factors such as a doctor's recommendation, expectations, peer effect, economic burden, desire to contribute to medical research, and family support, and (2) negative factors consisting of the side effects of drugs, drug safety, and problems guaranteeing patients' rights and interests. There are significant differences in liver cancer patients' awareness and attitudes towards clinical drug trials. Enhancing patient education and addressing their concerns can improve participation rates. Effective use of physician recommendations, financial incentives, and family support are crucial in encouraging patient involvement in clinical trials. Researchers should improve the awareness of liver cancer patients with regard to clinical drug trials and understand the factors that affect their participation. : The patients had no contributions in the design or conduct of the study, analysis or interpretation of the data, or in the preparation of the manuscript.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.